Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

563 - Role of consolidative radiation therapy after surgery in patients with stage IV rectal cancer


24 Nov 2018


Poster display - Cocktail


Radiation Oncology

Tumour Site

Colon and Rectal Cancer


Tahir Mehmood


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


T. Mehmood

Author affiliations

  • Radiation Oncology, Northwest General Hospital and Research Centre, 13014 - Peshawar/PK


Abstract 563


Radiotherapy (RT) and surgery are known to effectively palliate many symptoms of patients with metastatic rectal cancer (mRC). However, whether RT would provide survival benefit to mRC after surgery remains unclear.


A retrospective population-based cohort study was performed using the Surveillance, Epidemiology, and End Results Program (SEER) database. Patient demographics between the RT and no-RT groups were compared using Pearson Chi-Square tests. Propensity score (PS) matching and Cox proportional hazards regression analyses were performed to evaluate prognostic power of variables on cause-specific survival (CSS).


A total of 5520 mRC patients who have received surgery were identified in SEER database. Multivariable Cox regression analyses showed that RT was a protective factor of mRC patients after surgery in mRC patients (hazard ratio [HR] = 0.654, 95% confidence interval [CI] = 0.607-0.704, p < 0.001). PS matching produced 3887 mRC patients and univariable Cox regression analyses indicated that RT was associated with a significant improvement of CSS in mRC patients after surgery (HR = 0.455, 95%CI=0.422-0.491).


Using SEER database, we have identified that RT was associated with a significant survival advantage in the setting of mRC patients after surgery. This study strongly supports the use of RT after surgery for patients with mRC. In order to accurately define the role of RT in the comprehensive treatment for mRC patients, more prospective studies are clearly needed to be conducted.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study



Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.